Full Press Release Details
PORTLAND, ME--(Marketwire - June 5, 2008) - ImmuCell Corporation (NASDAQ: ICCC) today
announced that it has initiated the pivotal effectiveness field trial of
Planning and preparations for this trial began in July 2007. Completion of
the field trial is expected by year-end. Enrollment is targeted at several
hundred cows covering multiple locations in the major dairy sheds across
"Mast Out has shown strong performance in previous studies," commented
Dr. Joseph H. Crabb, vice president and chief scientific officer.
"However, this trial is being conducted under an FDA-approved pivotal
protocol, and, as such, will be the effectiveness bench mark for this
Mast Out is a Nisin-based intramammary infusion product that is being
developed as an alternative to traditional antibiotics used in the
treatment of mastitis in lactating dairy cows. The safety profile of Nisin
and its long history as a food preservative may allow for the sale of Mast
Out in the U.S. without a milk discard requirement, which would be a
significant competitive advantage. No other intramammary mastitis
treatment product has such a "zero discard" claim. Commercial introduction
of Mast Out in the United States is subject to approval by the U.S. Food
and Drug Administration, Center for Veterinary Medicine.
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries. Press releases and other
information about the Company are available at http://www.immucell.com.
Contact Information: Contact:
President and Chief Executive Officer
(207) 878-2770 Ext. 3106